Aashka Hospitals' audit record is split cleanly in two: qualified opinions for FY2022 and FY2023 over advances to a director and unconfirmed interest, then clean opinions from FY2024 onward. The clean-opinion switch came without visible resolution of those advances, and the only recurring exception since is the absence of an audit trail in the company's accounting software. The related-party record, auditor rotation, and regulatory history all deserve a retail investor's attention.
Key findings
- Audit opinion swung from qualified to clean without evidence the underlying advances were resolved
Critical- Singhi & Co. qualified the FY2022 opinion for multiple reasons, including advancing ₹28.7 crore to the managing director for land purchase without agreements provided for verification, plus advances of ₹2,861.50 lakh to three parties and ₹817.12 lakh to 14 parties. For FY2023, the auditor again qualified because the sale deed for the ₹28.67 crore advance to a director made in FY2021-22 was yet to be executed, and interest confirmations of ₹2.13 crore were not provided. From FY2024 onward, Parimal S. Shah & Co. issued unqualified opinions on the financial statements, with a separate reporting exception since FY2025 on the absence of an audit trail in Tally. - A ₹28.7 crore advance to the managing director sits against AOC-2 filings claiming no non-arm's-length contracts
Critical- In FY2021-22, Aashka Hospitals advanced ₹28.67 crore to a Director for land purchase, and the sale deed remained unexecuted as of the FY2022-23 audit report. The FY2022-23 auditor's report states agreements between the company and director were not provided for verification, though TDS was deducted and deposited. Every Form AOC-2 from FY2022-23 through FY2025-26 discloses no contracts or arrangements not at arm's length basis. - Statutory auditor rotated in 2023 to a firm that had just served as internal auditor
Major- Singhi & Co. served as statutory auditors for five years from the AGM held September 29, 2018, with their term expiring at the 11th AGM in 2023. Shareholders approved M/s. Parimal S. Shah & Co. as statutory auditors at the AGM held September 29, 2023. Parimal S. Shah & Co. had served as internal auditor for FY2021-22, and the board appointed them as internal auditors for FY2023-24 on 30 May 2023, the same fiscal year they became statutory auditors. - Repeated SEBI/BSE compliance actions and secretarial audit qualifications over FY2022-FY2024
Major- The Secretarial Audit Report for FY2023-24 recorded that BSE Limited imposed various fines for delay in submission under SEBI LODR, continuing from observations in the audit report dated August 28, 2023. The FY2022-23 secretarial audit recorded delayed filing of Half Yearly results, deviation in utilization of IPO proceeds, a pending SCORES complaint from November 22, 2022 not yet resolved, and vacancies from resignation of Independent Directors not filled within 3 months. The FY2022-23 report also recorded delay in filing Half Yearly results for period ended September 30, 2021 and deviation in utilization of IPO proceeds. - Borrowings are secured by substantial collateral owned by promoters, directors and their relatives
Major- Bank of India facilities are secured by collateral including equitable mortgage of NA land at Dharmoda, Dist Patan admeasuring 66,155 sq m owned by Mr. Rameshbhai Maganbhai Desai & Mr. Bipin Dineshchandra Shah. SREI Equipment Finance Ltd term loan is secured by registered mortgage of commercial land admeasuring 11,481 sq yards at Mouje-Dharisana owned by Mr. Bipin Shah and his brothers. The company states no loans/advances to promoters, directors, KMPs or related parties in FY2025-26. - Operating cash flow has been negative cumulatively over eight years despite positive reported profits
Major- Cumulative CFO over 8 years was ₹-14cr against cumulative PAT of ₹16cr. FY22 CFO was ₹-62.63cr against PAT of ₹2.37cr, the largest single-year divergence in the 8-year series. The last three years have been positive, with FY26 CFO of ₹7.79cr against PAT of ₹3.34cr, FY25 CFO of ₹9.19cr against PAT of ₹3.27cr, and FY24 CFO of ₹7.18cr against PAT of ₹2.36cr. No dividend was recommended for FY ended March 31, 2024 or FY2024-25. - An August 2026 restructuring MoU would create a 70%-owned combined entity that becomes a related party
Minor- Aashka Hospitals Ltd had no subsidiaries, associates or joint ventures during FY2022-23 through FY2025-26. On 8 Aug 2026, Aashka Hospitals entered a Memorandum of Understanding with Rhythm Medical Stores, Rhythm Multispeciality Hospital, Cardioplus Heart Care and Rhythm Medical & Heart Hospital for strategic restructuring into one company in which Aashka would hold 70% of total voting rights and capital. The newly emerged entity would become a related party to Aashka after the restructuring.
What to watch
- Strategic restructuring MoU. Completion and terms of the MoU with Rhythm Medical Stores, Rhythm Multispeciality Hospital, Cardioplus Heart Care and Rhythm Medical & Heart Hospital, announced 8 Aug 2026.
- Section 186 authorization. Shareholder approval outcome for authorization of investments, loans, guarantees and securities up to ₹50 Crores sought in the FY2025-26 AGM notice.
- CMD re-appointment. Special Resolution to be voted at the AGM following the FY2025-26 Annual Report, for term September 20, 2026 to September 19, 2029.
- ₹28.67 crore advance. Whether the advance to the managing director for land purchase is resolved or the sale deed executed, as the FY2022-23 audit report noted it remained pending.
- SCORES complaint. Resolution of the pending complaint from November 22, 2022, as noted in the Secretarial Audit Report dated August 28, 2023.
Bottom line: This is a record with a clean audit opinion for the last three years, but the path to that clean opinion runs through two qualified years over a ₹28.7 crore advance to the managing director that was never shown to be resolved. The risk character is one of disclosure and governance: a related-party advance that the AOC-2 filings do not acknowledge, an auditor rotation to a firm that was just the internal auditor, and a promoter family whose control is secured by both the boardroom and the collateral behind the company's borrowings. Watch whether the advance gets a sale deed, whether the restructuring MoU closes, and whether the Section 186 authorization passes.